Company Leadership

NEWS
Simon Shaw

Simon Shaw

Non-Executive Chairman

Simon Shaw joined Synairgen as executive Chairman on its inception in June 2003 and became non-executive Chairman in October of that year. He is Group Chief Financial Officer of Savills plc.

He was Chief Financial Officer of Gyrus Group PLC from 2003 until its sale to Olympus Corporation in 2008, having previously been Chief Operating Officer of Profile Therapeutics plc between 1998 and 2003. Between 1991 and 1997 he was a corporate financier, latterly at Hambros Bank Limited. He is a chartered accountant.

Richard Marsden

Richard Marsden

Chief Executive Officer

Richard Marsden joined Synairgen in a consulting role as General Manager in November 2003, was appointed to the Board as Managing Director in June 2004 and appointed Chief Executive Officer in September 2009. Between 1998 and 2003 he worked as Projects Manager and Cystic Fibrosis Business Development Manager at Profile Therapeutics plc, where he managed the Cystic Fibrosis business and played a major role in the development of its proprietary pharmaceutical unit, Profile Pharma Limited. Prior to this, he worked for Zimmer Limited, Genentech (UK) Limited and Roche Products Limited.

Dr Phillip Monk

Dr Phillip Monk

Chief Scientific Officer

Dr Phillip Monk joined Synairgen in October 2006 as Head of Bioscience Development and was appointed to the Board as Chief Scientific Officer in September 2009. Phillip was previously Director of the Respiratory and Inflammation Biology group at Cambridge Antibody Technology (‘CAT’) and led the scientific development of tralokinumab, an anti-IL-13 antibody being developed for the treatment of severe asthma.

Prior to joining CAT, he worked at Bayer AG within the respiratory disease therapeutic area, focusing on the development of novel therapies for asthma, COPD and cystic fibrosis.

John Ward

John Ward

Chief Financial Officer

John Ward joined Synairgen in October 2004 as Finance Director and was appointed Chief Financial Officer in March 2021. From December 1999 to July 2004 he was Chief Financial Officer and Company Secretary of Profile Therapeutics plc and was appointed to the Profile Therapeutics board in March 2003.

From 1996 to 1999 he was Finance Director of Rapid Deployment Group Limited, the UK holding company for the healthcare operations of Ventiv Health, Inc. Prior to joining Rapid Deployment he was a Director of Corporate Finance at Price Waterhouse. He is a chartered accountant.

Iain Buchanan

Iain Buchanan

Non-Executive Director

Iain Buchanan was appointed as a non-executive director in June 2010 and brings to the company over 40 years of management experience in the pharmaceutical and biotech industries. Most recently he was CEO of NOXXON Pharma AG based in Berlin and previously he was CEO of Novexel S.A. based in Paris. He joined Novexel from Vertex Pharmaceuticals where he established the European affiliate. Prior to Vertex, Iain managed the international licensee business of Cilag AG – a subsidiary of Johnson and Johnson – based in Switzerland. Iain serves as a non-executive director for Allecra Therapeutics GmbH and Aurealis Pharma AG.

Dr Bruce Campbell

Dr Bruce Campbell

Non-Executive Director

Dr Bruce Campbell joined Synairgen as a non-executive Director in April 2006. He has 50 years of drug development experience and has developed many drugs in a wide range of indications which are now on the market. He currently acts as a consultant to various companies including BenevolentAI and Syncona. Formerly he was Senior VP of International Development at Neurocrine Biosciences, Inc. (‘Neurocrine’). Prior to joining Neurocrine he worked for 27 years at Servier (United Kingdom), latterly as Scientific Director. In addition, he has also been a director and European Chairman of the Drug Information Association, a member of the European ICH Safety Working Party and a scientific advisor to IP Group plc. 

Theodora Harold

Theodora Harold

Non-Executive Director

Theodora Harold is an independent Non-Executive Director of Synairgen and Chair of the Audit Committee, since September 2021. She is also the CEO of Crescendo Biologics, having joined the company in 2016 and was previously the CFO and CBO. She has more than 20 years’ experience with both private and listed biotech SMEs and to date she has helped raise c.$200m for the sector. She was on the founding teams of both MISSION Therapeutics and PsiOxus Therapeutics where she was CFO, as well as having held executive roles with companies such as Cytomyx Holdings Plc and Orthomimetics. Theodora qualified as Chartered Accountant with PricewaterhouseCoopers and read Classics at Trinity College, Cambridge.

Prof. Sir Stephen Holgate CBE

Prof. Sir Stephen Holgate CBE

Non-Executive Director

Stephen Holgate is a co-founder of Synairgen and was appointed a non-executive director in June 2003. After qualifying in Medicine at Charing Cross Hospital Medical School, London he has pursued an academic career leading to his appointment in 1987 to his current position as Medical Research Council Clinical Professor of Immunopharmacology at the University of Southampton. His research interests have been largely focused on the cellular and molecular mechanisms of asthma that has involved use of both epidemiological and genetic approaches. He has published over 1,300 papers in peer-reviewed literature.

He is Member of the Horizon 2020 Science Panel for Health; Board Chair of the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs); Chairman of Defra’s Hazardous Substances Advisory Committee; Trustee and Chair of the Research Strategy Committee of Cancer Research UK; Trustee and Chair of the Grants Panel of the Great Ormond Street Hospital Children's Charity; Trustee and Chair of The Kennedy Trust for Rheumatology Research; Member of the Governing Body of Nuffield Council for Bioethics; and Member of the Natural Environment research Council. He serves on a number of Advisory Committees in industry, including scientific board member or advisor to a number of companies involved in developing new treatments for airways diseases.

Richard Marsden

Richard Marsden

Chief Executive Officer

Richard Marsden joined Synairgen in a consulting role as General Manager in November 2003, was appointed to the Board as Managing Director in June 2004 and appointed Chief Executive Officer in September 2009. Between 1998 and 2003 he worked as Projects Manager and Cystic Fibrosis Business Development Manager at Profile Therapeutics plc, where he managed the Cystic Fibrosis business and played a major role in the development of its proprietary pharmaceutical unit, Profile Pharma Limited. Prior to this, he worked for Zimmer Limited, Genentech (UK) Limited and Roche Products Limited.

Jody Brookes

Jody Brookes

Head of Clinical Operations

Jody Brookes joined Synairgen as a Clinical Research Nurse in 2004 and was appointed as Head of Clinical Operations in December 2011. Jody has led Synairgen’s clinical trial activity during this time. Prior to joining Synairgen she worked as a Clinical Research Nurse specialising in Respiratory trials at the University of Southampton, working on both commercial and non-commercial trials. 

Richard Hennings

Richard Hennings

Chief Commercial Officer

Richard Hennings joined Synairgen as Chief Commercial Officer in March 2021. Richard was previously VP & Commercial Head of Verona Pharma from 2017 up to the $200M Ph 3 financing raise in July ‘20. Between 1999 & 2017 he held Commercial leadership roles at Gilead Sciences, Novartis & AstraZeneca. During his 8 year Gilead tenure Richard led expansion of respiratory & anti-viral portfolios in the EU & US markets, launching inhaled Cayston® for Cystic Fibrosis & HIV treatment Stribild®. During his subsequent AstraZeneca assignment, Richard led Antibiotic Zavicefta® EU/ LATAM launch readiness and divestment of the antibiotics business unit to Pfizer.
Dr Phillip Monk

Dr Phillip Monk

Chief Scientific Officer

Dr Phillip Monk joined Synairgen in October 2006 as Head of Bioscience Development and was appointed to the Board as Chief Scientific Officer in September 2009. Phillip was previously Director of the Respiratory and Inflammation Biology group at Cambridge Antibody Technology (‘CAT’) and led the scientific development of tralokinumab, an anti-IL-13 antibody being developed for the treatment of severe asthma.

Prior to joining CAT, he worked at Bayer AG within the respiratory disease therapeutic area, focusing on the development of novel therapies for asthma, COPD and cystic fibrosis.

Brooke Clarke

Brooke Clarke

Head of Communications

Brooke Clarke joined in September 2021 as Head of Communications, bringing more than 30 years of strategic communications and corporate affairs experience.  From 2016-2021, Brooke was global head of communications and corporate affairs at the FTSE100 company Hikma plc, and prior to that she held several senior communications roles at Shire plc from 2001-2016 including leading CSR, internal communications and corporate brand. Prior to joining Shire, Brooke worked as a communications consultant in New York and London advising companies including Procter & Gamble, the World Economic Forum and Starbucks, among others. She is a graduate of the University of Michigan in Ann Arbor, and received an MSc from Birkbeck, University of London.

John Ward

John Ward

Chief Financial Officer

John Ward joined Synairgen in October 2004 as Finance Director and was appointed Chief Financial Officer in March 2021. From December 1999 to July 2004 he was Chief Financial Officer and Company Secretary of Profile Therapeutics plc and was appointed to the Profile Therapeutics board in March 2003.

From 1996 to 1999 he was Finance Director of Rapid Deployment Group Limited, the UK holding company for the healthcare operations of Ventiv Health, Inc. Prior to joining Rapid Deployment he was a Director of Corporate Finance at Price Waterhouse. He is a chartered accountant.

Dr. Gareth Walters

Dr. Gareth Walters

Chief Regulatory Officer

Gareth Walters joined Synairgen in October 2021, and brings a wide range of experience from preclinical, to marketing authorisation, through to post-approval and commercialisation. Before joining Synairgen, Gareth served as Global Regulatory Affairs Head (Research & Early Development) and Head of European Regulatory Affairs for Chugai Pharmaceuticals, where he led strategic and operational regulatory activities in Europe, Japan and the US. Prior to his time at Chugai, he held various senior regulatory and executive management and Board roles at several pharmaceutical and biotech companies, as well as commercial and clinical positions at Roche. During this time he played a key role in bringing innovative new medicines to the market, including in the US and Europe.

Richard Francis

Richard Francis

Head of CMC

Richard Francis joined in September 2021 as Head of CMC, bringing more than 35 years’ experience in the development, manufacturing, regulatory approval and commercialization of many biopharmaceutical products including Cablivi®, Orthoclone OKT3®, Remicade®, and ReoPro®.

Dr. Victoria Tear

Dr. Victoria Tear

Head of Laboratory

Victoria Tear joined Synairgen as a Research Scientist in July 2007 and was appointed Head of Laboratory in April 2019. Before joining Synairgen, she completed a PhD investigating therapies for cystic fibrosis at the University of Portsmouth and worked in drug discovery at Pfizer. Victoria has expertise in non-clinical aspects of drug discovery and development with both small molecules and therapeutic proteins. She has worked on internal programmes including SNG001 (inhaled interferon beta) as well as external collaborations including the development of a small molecule LOXL2 inhibitor for the treatment of fibrosis.

Board committee membership

Members Audit Committee Remuneration & Nomination Committee
Simon Shaw:
Non-Executive Chairman
Richard Marsden:
Chief Executive Officer
Dr Phillip Monk:
Chief Scientific Officer
John Ward:
Chief Financial Officer
Iain Buchanan:
Non-Executive Director
Dr Bruce Campbell:
Non-Executive Director
Theodora Harold:
Non-Executive Director
Prof. Sir Stephen Holgate CBE:
Non-Executive Director
Chairperson Member

Investors